Herceptin biosimilar Herzuma launched in Europe
Mundipharma announced that its network of companies has kicked off the rollout of Celltrion’s Herceptin biosimilar Herzuma in Europe.
Read More
Tag: Herzuma
US delay for Celltrion’s Rituxan, Herceptin biosimilars
The US Food and Drug Administration has rejected Celltrion’s submissions for biosimilars to Roche drugs Rituxan and Herceptin.
Read More
Napp secures distribution rights to Celltrion’s Herzuma
Napp Pharmaceuticals has secured itself exclusive UK distribution rights to Celltrion Healthcare’s Herceptin biosimilar Herzuma.
Read More
Green light for Celltrion’s Herceptin biosimilar
The European Commission has approved Celltrion Healthcare’s Herzuma, a biosimilar of Roche/Genentech’s blockbuster Herceptin.
Read More
Seven therapies backed for EU approval
Seven therapies have been put forward for approval in the European Union, bringing closer new options for a range of conditions including Crohn’s disease, diabetes and cancer.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
